Mecapegfilgrastim Prevents Neutropenia and Radiation Esophagitis
Status:
Unknown status
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
Evaluation of the efficacy and safety of Mecapegfilgrastim for the prevention of neutropenia
and radiation esophagitis after hyperfractionation in patients with limited-stage small cell
lung cancer
Phase:
N/A
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital